Previous 10 | Next 10 |
home / stock / teva / teva articles
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reser...
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the consensus of $0.43. The comp...
In recent decades, Israel has become a hotspot for innovation. Yet the breakout of a war between Israel and Hamas, which controls the Palestinian t...
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are trading lower by 2.7% to $9.17 Monday morning amid conflict in the company's ho...
Benzinga AI Powerhouse: Palantir And PwC Team Up To Accelerate Data-Driven Operations Palantir Technologies Inc (NYSE: PLTR) is expanding its...
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and co-commercializ...
Editor's note: This article has been updated with more details from the Access to Medicine Foundation's study. Despite significa...
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO Alibaba Group Holding Limited (NYSE: BABA) stock is trading higher Wedne...
A federal judge in Massachusetts has overturned a $176.5 million jury verdict against Eli Lilly And Co (NYSE: LLY). T he verdict, wh...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...